Health Care Equipment

Inspire Medical

Bank of America's Steed Reaffirms Buy Rating on Guidant Medical, Maintains $53 Price Target

Inspire Medical released FY2026 Q1 earnings on May 4 After-Market (EST), actual revenue USD 204.58 M (forecast USD 200.03 M), actual EPS USD -0.3935 (forecast USD -0.61)

Inspire Medical to Release FY2026 Q1 Earnings on May 4 After-Market EST, Forecast Revenue USD 200.03 M, EPS USD -0.5616

Inspire Medical released FY2025 earnings on February 11 After-Market EST, actual revenue USD 911.98 M (forecast USD 909.29 M), actual EPS USD 4.8899 (forecast USD 0.9764)

Inspire Medical released FY2025 Q4 earnings on February 11 After-Market EST, with forecasted revenue of USD 266.22 M and EPS of USD 0.6669

Inspire Medical Reports Q4 2025 Financials Exceeding Expectations

Inspire Medical Systems Reports 182% YoY Q4 Net Income Growth and Launches Inspire V System

Inspire Medical to Release FY2025 Q4 Earnings on February 11 After-Market (EST), Forecast Revenue USD 266.22 M, EPS USD 0.6669

Inspire Medical Evaluated by 19 Analysts, Target Price Raised

Inspire Medical Reports Q4 2025 Earnings and Provides 2026 Revenue Guidance

Inspire Medical Systems expects 10%-11% revenue growth in 2026

Wolfe Research Upgrades Inspire Medical's Rating to 'Outperform' and Shares Rise

Stifel Upgrades Inspire Healthcare's Stock Rating to Buy

Analyst Wood and Piper Sandler Maintain Buy Rating for Inspire Medical

Fishbin Analyst Reiterates Hold Rating on Qiduif Medical with Price Target

Inspire Medical released FY2025 9 Months Earnings on November 3 After-Market EST, actual revenue USD 418.4 M, actual EPS USD -0.0217

Inspire Medical released FY2025 Q3 earnings on November 3 After-Market EST, actual revenue USD 224.5 M (forecast USD 220.39 M), actual EPS USD 0.3386 (forecast USD -0.1976)

Inspire Medical to release FY2025 Q3 earnings on November 3 After-Market EST, forecast revenue USD 220.39 M, EPS USD -0.1976

Inspire Medical released FY2025 Semi-Annual earnings on August 4 After-Market (EST), actual revenue USD 418.4M, actual EPS USD -0.0202

Inspire Medical released FY2025 Q2 earnings on August 4 After-Market (EST), actual revenue USD 217.09 M (forecast USD 214.34 M), actual EPS USD -0.1217 (forecast USD 0.2099)

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

Micware

BiomX

MicroAlgo

Tradr 2X Long XNDU Daily ETF

INSP

Analyst Travis Steed from Bank of America Securities has reiterated a Hold rating on Inspire Medical Systems, maintaining a price target of $53. The decision is influenced by reimbursement uncertainties following the AMA's recent coding decision, which limits near- to medium-term visibility. The potential delay in new codes and reimbursement changes could extend uncertainty to 2029, leading Steed to view the risk/reward as balanced.

Tip Ranks

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Analyst Maintains Hold on Inspire as Reimbursement Uncertainty Persists; $53 Price Target Reaffirmed

MMSI

SBIO

Non-Invasive Monitoring Systems, Inc. has announced a $200,000 promissory note with Frost Gamma Investments Trust and a $100,000 note with its Chairman, Jane Hsiao, both maturing on June 30, 2026, at an 11% interest rate. This insider financing highlights the company's reliance on major shareholders for short-term liquidity, indicating a close alignment between management and capital structure. The company operates in the medical technology sector, with significant insider ownership.

Merit Medical

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

SPDR S&P Health Equip

iShares US Medical Devices

Non-Invasive Monitoring Secures Insider-Funded Short-Term Financing

UBS Group AG has reduced its stake in Inspire Medical Systems, Inc. by 12.1%, selling 56,407 shares during the 4th quarter, leaving it with 411,329 shares valued at approximately $37.94 million. Other institutional investors have also adjusted their holdings. Inspire Medical's stock opened at $45.48, down 0.5%, with a market cap of $1.31 billion. The company reported a quarterly EPS of $0.10, exceeding estimates, and has set FY 2026 guidance at 0.750-1.250 EPS. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $85.00.

Market Beat

UBS Group AG

UBS Group AG Sells 56,407 Shares of Inspire Medical Systems, Inc. $INSP

Inspire Medical Systems (NYSE:INSP) reached a new 12-month low after JPMorgan Chase downgraded its price target from $67 to $54. The stock traded as low as $44.41 and closed at $48.24, with a trading volume of 4,487,693 shares. Analysts have mixed ratings, with four recommending a buy and fifteen a hold. The company also cut its FY-2026 guidance significantly, citing reimbursement issues and operational challenges. Institutional investors hold 94.91% of the stock, reflecting strong interest despite recent downgrades.

JPMorgan Chase

Eli Lilly

Evercore

Truist Financial

Stifel Financial

Mizuho Financial

Mizuho Financial Group, Inc.

Wells Fargo

Principal Financial

Fifth Third Bancorp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Fifth Third Bancorp Pref Share FITBO 4.95 Perp 09/30/24 K

FIFTH THIRD BANK PREF SHARE FITB V6.625 P12/31/49 I

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

Fifth Third Bancorp Depositary Shs B Ser A Repr 1/40 6 % Perp Pfd Registered Shs B Ser A

Inspire Medical Systems (NYSE:INSP) Reaches New 12-Month Low on Analyst Downgrade

Inspire Medical Systems (INSP) has experienced a significant decline in share price, down 70.19% over the past year and 47.71% year-to-date, leading to a market valuation of approximately $1.58 billion. The stock closed at $48.25, which is considerably below its estimated fair value of $79.42. Despite recent challenges, including delays in the rollout of its next-generation system, analysts suggest that the company may be undervalued, with potential for revenue growth as market conditions improve. Investors are encouraged to explore other opportunities in the healthcare sector.

Simplywall

Assessing Inspire Medical Systems (INSP) Valuation After Prolonged Share Price Weakness

BRBR

IPGP

ADEA

OSIS

ADTN

SHOP

PCOR

GeneDx(WGS) fell 49.2%, with a trading turnover 393.0 Million USD, and a year-to-date fell 73.5%. Bellring Brands(BRBR) fell 38.77%, with a trading turnover 272.8 Million USD, and a year-to-date fell 60.2%. IPG Photonics(IPGP) fell 25.74%, with a trading turnover 280.2 Million USD, and a year-to-date rose 26.9%.

Top Gainers&Losers

GeneDx

Bellring Brands

IPG Photonics

Adeia

Adtran

Shopify 

Procore Tech

Fresenius Medical Care

Top 10 US Stock Losers (5.5)

Inspire Medical Systems' shareholders approved significant governance changes at the April 30, 2026 annual meeting, including the declassification of the board to allow annual elections starting in 2029. The amendments aim to enhance board accountability and align with corporate governance trends. Shareholders also elected three directors, ratified Ernst & Young as the auditor, and supported executive compensation plans. Despite a Hold rating from analysts with a $55 price target, the stock faces challenges due to earnings outlook resets and technical concerns, although it has strong fundamentals.

Inspire Medical Shareholders Approve Board Declassification and Governance Changes

JPMorgan Chase & Co. has lowered its price target for Inspire Medical Systems (NYSE:INSP) from $67.00 to $54.00, maintaining a "neutral" rating. This adjustment suggests a potential upside of 11.94% from the stock's previous close. Other brokerages have also revised their ratings, with Piper Sandler and Zacks Research downgrading their assessments. Despite these changes, four analysts still rate the stock as a Buy, while the consensus rating remains a Hold with a target price of $85.00. Inspire Medical recently reported earnings that exceeded expectations, showing modest revenue growth.

Defiance Daily Target 2X Long JPM ETF

Piper Sandler Cos

Zacks Quality International ETF

Zacks Focus Growth ETF

Zacks Small/Mid Cap ETF

Nano Labs

ROYAL BANK OF CANADA

Bank of Montreal

Canadian Imperial Bank Comm

Morgan Stanley

K Wave Media

Cushman & Wakefield

SEAPEAK LLC 9% CUM RED PERP PREF UNITS SER A

Childrens Place

Harvard Ave Acquisition - Unit

Medley, Inc.

QuantumScape

Quantum-Si

Squarex Pharmaceutical Corp

Manhattan Associates

Hennessy Advisors

Brown Advisory US Smaller Companies PLC GBP

F&C Asset Management PLC

Arcadian Asset

Liontrust Asset Management PLC

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

K WAVE MEDIA LTD C/WTS 14/05/2030(TO PUR COM)

SEAPEAK LLC 8.5% CUM RED PERP PFD UNTS FXD FLT SER B

Quantum - Si - CW27

Hennessy Advisors Pref Share HNNAZ 4.875 12/31/26

JPMorgan Chase & Co. Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $54.00

Truist Financial analyst Richard Newitter has maintained a Hold rating on Inspire Medical Systems (INSP) with a price target of $50.00. Newitter, a 4-star analyst, has an average return of 6.6% and a 45.53% success rate. KeyBanc also issued a Hold rating for the company, while Stifel Nicolaus maintained a Buy rating on the same day.

Boston Scientific

Insulet

Medtronic

KeyCorp

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Truist Financial Sticks to Its Hold Rating for Inspire Medical Systems (INSP)

Inspire Medical Systems, Inc. (INSP) shares fell over 20% in premarket trading after reporting a Q1 net loss of $11.29 million, compared to a profit of $2.99 million last year. The company lowered its FY26 revenue guidance to $825-$875 million, down from $950 million-$1 billion, due to reimbursement issues with its Inspire V system. Adjusted EPS estimates were also reduced significantly. CEO Tim Herbert expressed optimism for revenue growth in 2027 despite current challenges.

nasdaq

Nasdaq

Inspire Medical Systems Plunges On Q1 Results; Lowers FY26 Guidance; Expects Revenue Growth In 2027

Inspire Medical(INSP.US)